
Opinion|Videos|March 3, 2025
The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
Panelists discuss how stakeholders can enhance biosimilar uptake through coordinated efforts in financial alignment, patient-centric pricing, professional education, simplified administrative processes, and collaborative data exchange.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How can different stakeholders such as providers, health systems, insurance providers, and pharmacy benefit managers work together more efficiently to optimize the uptake of biosimilars?
Advertisement
Related to this article

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.

The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.

Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.

Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.

Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
4
5 Things to Know if Retatrutide Is Classified as a Biologic
5




